AFA responds to approval of Alzheimers Drug by FDA Advisory Committee [Video]

FAIRBANKS, Alaska (KTVF) – The U.S. Food and Drug Administration (FDA) Advisory Committee, has approved the Alzheimer’s drug, donanemab. This new drug works by slowing the progression of the disease when administered within the early stages of Alzheimer’s.

In phase three of the clinical trials reported in July of 2023, the drug significantly slowed the cognitive and functional decline in those living with early Alzheimer’s disease.

On June 11, The Alzheimer’s Foundation of America responded to the FDA Advisory Committee’s approval of donanemab by saying:

“We are encouraged by the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee’s unanimous approval of donanemab and are optimistic that, if fully approved by the FDA, it will make a positive difference in the lives of individuals living with Alzheimer’s disease and their family caregivers. The FDA should keep the review process moving forward and set a date for final determination.”

“This is a positive sign of continuing progress, but we must keep moving …